101 related articles for article (PubMed ID: 15611270)
1. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.
Vuola JM; Keating S; Webster DP; Berthoud T; Dunachie S; Gilbert SC; Hill AV
J Immunol; 2005 Jan; 174(1):449-55. PubMed ID: 15611270
[TBL] [Abstract][Full Text] [Related]
2. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.
Webster DP; Dunachie S; Vuola JM; Berthoud T; Keating S; Laidlaw SM; McConkey SJ; Poulton I; Andrews L; Andersen RF; Bejon P; Butcher G; Sinden R; Skinner MA; Gilbert SC; Hill AV
Proc Natl Acad Sci U S A; 2005 Mar; 102(13):4836-41. PubMed ID: 15781866
[TBL] [Abstract][Full Text] [Related]
3. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin.
Vordermeier HM; Rhodes SG; Dean G; Goonetilleke N; Huygen K; Hill AV; Hewinson RG; Gilbert SC
Immunology; 2004 Jul; 112(3):461-70. PubMed ID: 15196215
[TBL] [Abstract][Full Text] [Related]
4. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults.
Ogwang C; Kimani D; Edwards NJ; Roberts R; Mwacharo J; Bowyer G; Bliss C; Hodgson SH; Njuguna P; Viebig NK; Nicosia A; Gitau E; Douglas S; Illingworth J; Marsh K; Lawrie A; Imoukhuede EB; Ewer K; Urban BC; Hill AVS; Bejon P;
Sci Transl Med; 2015 May; 7(286):286re5. PubMed ID: 25947165
[TBL] [Abstract][Full Text] [Related]
5. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
O'Hara GA; Duncan CJ; Ewer KJ; Collins KA; Elias SC; Halstead FD; Goodman AL; Edwards NJ; Reyes-Sandoval A; Bird P; Rowland R; Sheehy SH; Poulton ID; Hutchings C; Todryk S; Andrews L; Folgori A; Berrie E; Moyle S; Nicosia A; Colloca S; Cortese R; Siani L; Lawrie AM; Gilbert SC; Hill AV
J Infect Dis; 2012 Mar; 205(5):772-81. PubMed ID: 22275401
[TBL] [Abstract][Full Text] [Related]
6. Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice.
Pearson FE; McNeilly CL; Crichton ML; Primiero CA; Yukiko SR; Fernando GJ; Chen X; Gilbert SC; Hill AV; Kendall MA
PLoS One; 2013; 8(7):e67888. PubMed ID: 23874462
[TBL] [Abstract][Full Text] [Related]
7. Impact of ChAdOx1 or DNA Prime Vaccination on Magnitude, Breadth, and Focus of MVA-Boosted Immunogen-Specific T Cell Responses.
Olvera A; Romero-Martin L; Oriol-Tordera B; Rosas-Umbert M; Escribà T; Mothe B; Brander C
Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543913
[TBL] [Abstract][Full Text] [Related]
8. Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens.
Barrett JR; Silk SE; Mkindi CG; Kwiatkowska KM; Hou MM; Lias AM; Kalinga WF; Mtaka IM; McHugh K; Bardelli M; Davies H; King LDW; Edwards NJ; Chauhan VS; Mukherjee P; Rwezaula S; Chitnis CE; Olotu AI; Minassian AM; Draper SJ; Nielsen CM
Front Immunol; 2023; 14():1193079. PubMed ID: 38299155
[TBL] [Abstract][Full Text] [Related]
9. One Group's Historical Reflections on DNA Vaccine Development.
Fynan EF; Lu S; Robinson HL
Hum Gene Ther; 2018 Sep; 29(9):966-970. PubMed ID: 30129778
[TBL] [Abstract][Full Text] [Related]
10. DNA Vaccines: History, Molecular Mechanisms and Future Perspectives.
Pagliari S; Dema B; Sanchez-Martinez A; Montalvo Zurbia-Flores G; Rollier CS
J Mol Biol; 2023 Dec; 435(23):168297. PubMed ID: 37797831
[TBL] [Abstract][Full Text] [Related]
11. Memory CD8+ T cell-mediated protection against liver-stage malaria.
Hassert M; Arumugam S; Harty JT
Immunol Rev; 2023 Jul; 316(1):84-103. PubMed ID: 37014087
[TBL] [Abstract][Full Text] [Related]
12. Controlled Human Infection Models To Accelerate Vaccine Development.
Choy RKM; Bourgeois AL; Ockenhouse CF; Walker RI; Sheets RL; Flores J
Clin Microbiol Rev; 2022 Sep; 35(3):e0000821. PubMed ID: 35862754
[TBL] [Abstract][Full Text] [Related]
13. The use of viral vectors in vaccine development.
Travieso T; Li J; Mahesh S; Mello JDFRE; Blasi M
NPJ Vaccines; 2022 Jul; 7(1):75. PubMed ID: 35787629
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus DNA Polymerase Loses Fidelity on a Stretch of Eleven Homocytidines during Pre-GMP Vaccine Preparation.
Hannoun Z; Wee EG; Crook A; Colloca S; Di Marco S; Hanke T
Vaccines (Basel); 2022 Jun; 10(6):. PubMed ID: 35746566
[TBL] [Abstract][Full Text] [Related]
15. Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response.
Rosenbaum P; Tchitchek N; Joly C; Rodriguez Pozo A; Stimmer L; Langlois S; Hocini H; Gosse L; Pejoski D; Cosma A; Beignon AS; Dereuddre-Bosquet N; Levy Y; Le Grand R; Martinon F
Front Immunol; 2021; 12():645210. PubMed ID: 33959127
[TBL] [Abstract][Full Text] [Related]
16. Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime/Boost Time Interval on the Immune Response in Non-human Primates.
Marcus H; Thompson E; Zhou Y; Bailey M; Donaldson MM; Stanley DA; Asiedu C; Foulds KE; Roederer M; Moliva JI; Sullivan NJ
Front Immunol; 2021; 12():627688. PubMed ID: 33790899
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Virus-Like Particles and Capsomeres Induce Similar CD8
Pattinson DJ; Apte SH; Wibowo N; Rivera-Hernandez T; Groves PL; Middelberg APJ; Doolan DL
Front Immunol; 2020; 11():564627. PubMed ID: 33133076
[TBL] [Abstract][Full Text] [Related]
18. Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines.
Hu Z; Jiang W; Gu L; Qiao D; Shu T; Lowrie DB; Lu SH; Fan XY
J Mol Med (Berl); 2019 Dec; 97(12):1685-1694. PubMed ID: 31786669
[TBL] [Abstract][Full Text] [Related]
19. Vaccination With Sporozoites: Models and Correlates of Protection.
Goh YS; McGuire D; Rénia L
Front Immunol; 2019; 10():1227. PubMed ID: 31231377
[TBL] [Abstract][Full Text] [Related]
20. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.
Volz A; Sutter G
Adv Virus Res; 2017; 97():187-243. PubMed ID: 28057259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
